Northway Biotech
16.5.2023 14:32:41 CEST | ACCESS Newswire | Press release
KIEL, GERMANY / ACCESSWIRE / May 16, 2023 / tiakis Biotech AG (tiakis), in collaboration with its CDMO partner Northway Biotech, is pleased to announce the successful completion of a technology transfer and ramp-up of manufacturing capabilities for Tiprelestat, a pioneering anti-inflammatory and tissue-protective drug being developed for the prevention of postoperative inflammatory complications following major surgery, treatment of COVID-19 and pulmonary arterial hypertension. For the first time worldwide, a clinical trial is being supported by Tiprelestat study material produced at an industrial fermentation scale, representing a ten-fold increase in manufacturing potential to 3,000 L.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.tiakis Biotech AG and Northway Biotech: Successful Tech Transfer and Expansion of Manufacturing Capabilities for Tiprelestat
"The marked increase in manufacturing capabilities lays the foundation for the next stage of tiakis' development programs, with the recent start of our COMCOVID phase Ib/II clinical trial being a prime example," said Martin Voss, tiakis Biotech AG co-CEO.
The enhanced production capabilities is a result of the successful completion of a technology transfer and subsequent ramp-up program, achieved in a short time through close collaboration with end-to-end biologics CDMO Northway Biotech, based in Vilnius, Lithuania.
Reflecting on this milestone, Vladas Algirdas Bumelis, CEO of Northway Biotech, stated: "The confidence our partners have placed in our two-decade-long expertise has enabled us to collaboratively scale up the process and meet tiakis' deadlines. Our state-of-the-art 3,000 L stainless-steel fermenter train was utilized to carry out the implementation successfully. We extend our sincere well-wishes to our partners as they move forward with their innovative drug through clinical trials, and we look forward to future collaborations."
André Markmann, VP Business Development of Northway Biotech, added: "This partnership exemplifies our commitment to assist our partners in achieving their objectives by leveraging our technical expertise and operational capabilities. We are immensely proud to be part of this groundbreaking project, which addresses a significant unmet medical need."
By attaining this pharmaceutical and technological milestone, tiakis and Northway Biotech have demonstrated their capabilities to pave the way towards groundbreaking achievements as pioneers in their respective fields. The success of this fast-paced project is characterized by strong collaborative interaction, mutual trust, and flexibility between the two companies.
About Tiprelestat
tiakis biopharmaceutical drug candidate Tiprelestat promises an excellent therapeutic benefit-risk profile for use as an anti-inflammatory and tissue-protective drug. Tiprelestat is identical to the human protein elafin with high specificity for tissue-destroying and inflammation-promoting proteases. The development program of Tiprelestat is focused on the late-stage development of Tiprelestat in major surgery and early-stage development in pulmonary arterial hypertension (PAH) and COVID-19.
About tiakis Biotech AG
tiakis focuses on the discovery and development of therapeutic solutions based on its innovative biopharmaceutical Tiprelestat for life-threatening surgeries and life-threatening diseases such as PAH and COVID-19. tiakis seeks partners and investors for the development, commercial-scale manufacturing, marketing and distribution of the product. The company tiakis Biotech AG is located in Kiel, Germany (www.tiakis.bio).
About Northway Biotech
Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced, professional team executes projects at any stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company's wide-ranging expertise and vertically integrated service offering translate to the ability to rapidly execute multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development and commercial manufacturing. Northway Biotech is a privately owned company founded in 2004 and located in Vilnius, Lithuania, London, United Kingdom, and in Waltham, MA, US. Further information can be found on Northway's website www.northwaybiotech.com.
Contact Information
Vladas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com
SOURCE: Northway Biotech
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/755218/tiakis-Biotech-AG-and-Northway-Biotech-Successful-Tech-Transfer-and-Expansion-of-Manufacturing-Capabilities-for-Tiprelestat
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Datavault AI Inc. (NASDAQ: DVLT) and WiSA Technologies Announce the Goho LS7 2.0 and 5.1 Home Theater Systems with WiSA E Wireless Connectivity23.6.2026 16:10:00 CEST | Press release
WiSA Technologies, a Datavault AI Company, powers wireless connectivity for two new home theater and karaoke systems from Goho, a brand of Goldhorn WISA E solves critical cross-brand interoperability problems, providing ubiquity on an enterprise scale for another of the world's premium acoustic brands. PHILADELPHIA, PA / ACCESS Newswire / June 23, 2026 / Datavault AI Inc. (NASDAQ:DVLT), through its Acoustic Sciences division's WiSA Technologies, today announced integration of the WiSA E Enterprise module in the new LS7 2.0 and 5.1 wireless home audio and karaoke systems from Goho, a brand of Goldhorn. These two stunning new systems are designed to bring high-definition two-channel and immersive 5.1 channel surround sound into the home entertainment environment with the simplicity and reliability of WiSA wireless audio transmission. "Goldhorn has built a strong reputation for delivering premium audio components to the mobile audio market, and we are very excited to enter the home audio
FINOS Launches AI Fund to Amplify the Collective Voice of the Financial Services Industry and Accelerate Responsible Agentic AI Adoption23.6.2026 10:00:00 CEST | Press release
Founding premier members DTCC, Morgan Stanley, RBC and NatWest join forces to collectively invest in open source AI, to advance common governance, controls, specifications, reference implementations, and intra and inter-firm agentic workflows for financial services, helping the industry shape safer AI adoption, reduce fragmentation, and accelerate real-world implementation. LONDON, UK / ACCESS Newswire / June 23, 2026 / The Fintech Open Source Foundation (FINOS) today announced the establishment of the FINOS AI Fund and the formation of its dedicated Governing Board. Anchored by Founding Premier Members The Depository Trust & Clearing Corporation (DTCC), Morgan Stanley, Royal Bank of Canada (RBC), and NatWest, the Fund is designed to help the industry collectively shape the governance, standards, and implementation foundations needed for responsible agentic AI adoption in regulated financial services. The Case for an Industry-Led AI Approach in Financial Services General AI technology
CTO Confidence in Scaling AI Falls for Third Straight Year, Akkodis Report Finds23.6.2026 06:45:00 CEST | Press release
"What CTOs Think 2026: Scaling the agentic enterprise with confidence" reveals for the first time, innovation, not efficiency, as the primary driver of digital investment, signaling a move from cost-focused optimization toward growth. ZURICH, SWITZERLAND / ACCESS Newswire / June 23, 2026 / New research released today by Akkodis, a global leader in digital engineering consulting and part of the Adecco Group, shows that CTO confidence in scaling AI is declining, falling to 48% in 2026 from 82% in 2024 - even as AI adoption accelerates and enterprises face growing pressure to turn ambition into execution at scale. Image: What CTOs Think 2026: Scaling the agentic enterprise with confidence. Source: Akkodis The third edition of Akkodis' What CTOs Think report, What CTOs Think 2026: Scaling the agentic enterprise with confidence, features insights from 500 Chief Technology Officers (CTOs) as part of the Adecco Group's Business Leaders 2026 research of 2,000 C-suite executives, The human prem
LiberNovo Prime Sale Fully Launches June 23: Full Chair Lineup and Accessories, Up to 49% Off23.6.2026 04:00:00 CEST | Press release
The limited Omni Premium Bundle headlines a flash sale across the EU and UK, stacked with tiered gifts, a prize wheel, and triple loyalty points, from June 23 through July 11. HONG KONG, HK / ACCESS Newswire / June 22, 2026 / LiberNovo today opened one of its biggest sales of the year. From June 23 through July 11, the entire collection goes on sale across the EU and UK with savings of up to 49% off, and the headline deal is the Omni Premium Bundle: a limited flash-sale price on the original Omni, starting from €939 ( £869) up to 49% off, the chair that started it all, available only while clearance stock lasts. Accessories and the rest of the range join at Prime Sale pricing too, making it the best time of the year to build your complete setup. Every LiberNovo chair is built on the world's first dynamic ergonomic design. A flexible backrest bends and moves with you as you shift, lean, and change position, so your support follows your body instead of holding you in one pose. A powered
Leggett Dynamics Launches Mid-Class Massage System & Makes Luxury Comfort Accessible on High-Volume Programs22.6.2026 13:00:00 CEST | Press release
DETROIT, MI / ACCESS Newswire / June 22, 2026 / Leggett Dynamics today launched its Mid-Class Massage System (MCM), a breakthrough non-electronic innovation that makes premium massage more accessible beyond the luxury vehicle segment. Now in production with a global OEM, MCM was also shortlisted for the 2026 Auto Tech Partnership Award for industry-leading innovation and collaboration. Breakthrough by Design MCM creates a distinctive massage experience with a compact 30 x 35 mm module that uses the Coandă effect, an air jet's natural tendency to follow a curved surface. With no electronics or moving parts, it reduces complexity and cost, making a premium experience accessible to more vehicle segments and consumers. Balancing Innovation, Speed and Cost "Automakers must balance innovation, speed and cost while consumers expect more personalized, affordable, premium experiences," said Julien Rea, VP of Global Innovation & Engineering at Leggett Dynamics. "Leggett Dynamics' Mid-Class Massa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom